{
 "awd_id": "1641077",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "NSF/FDA Scholar In Residence: Quantitative Characterization of Near-infrared Fluorescence Molecular Imaging Systems: 3D-printed Biomimetic Phantoms and In vivo Validation",
 "cfda_num": "47.041",
 "org_code": "07020000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Leon Esterowitz",
 "awd_eff_date": "2017-01-01",
 "awd_exp_date": "2018-12-31",
 "tot_intn_awd_amt": 86868.0,
 "awd_amount": 86868.0,
 "awd_min_amd_letter_date": "2016-07-13",
 "awd_max_amd_letter_date": "2016-07-13",
 "awd_abstract_narration": "ABSTRACT\r\nPI: Chen, Yu \r\nProposal Number:1641077 \r\n\r\nThe PI will develop advanced methods for characterizing minimally-invasive diagnostic medical devices. The research will facilitate the development and standardized performance testing of novel biophotonic technologies for early disease detection and image-guided surgery.  \r\n\r\n3D-printed biomimetic phantoms for the performance testing of near-infrared spectroscopy systems (NIRS) will be developed and the PI will investigate near-infra-red (IR) fluorescence (NIRF) image quality through in vivo and phantom-based measurements to explore the basis for developing standards that can be used to validate NIRF imaging systems. The development of novel biomimetic phantoms for noninvasive fluorescence molecular imaging (FMI) will elucidate optimal fabrication approaches that influence the effectiveness of 3D-printed phantoms.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "ENG",
 "org_dir_long_name": "Directorate for Engineering",
 "div_abbr": "CBET",
 "org_div_long_name": "Division of Chemical, Bioengineering, Environmental, and Transport Systems",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Yu",
   "pi_last_name": "Chen",
   "pi_mid_init": "",
   "pi_sufx_name": "",
   "pi_full_name": "Yu Chen",
   "pi_email_addr": "ychen8@umass.edu",
   "nsf_id": "000505109",
   "pi_start_date": "2016-07-13",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "University of Maryland, College Park",
  "inst_street_address": "3112 LEE BUILDING",
  "inst_street_address_2": "",
  "inst_city_name": "COLLEGE PARK",
  "inst_state_code": "MD",
  "inst_state_name": "Maryland",
  "inst_phone_num": "3014056269",
  "inst_zip_code": "207425100",
  "inst_country_name": "United States",
  "cong_dist_code": "04",
  "st_cong_dist_code": "MD04",
  "org_lgl_bus_name": "UNIVERSITY OF MARYLAND, COLLEGE PARK",
  "org_prnt_uei_num": "NPU8ULVAAS23",
  "org_uei_num": "NPU8ULVAAS23"
 },
 "perf_inst": {
  "perf_inst_name": "University of Maryland College Park",
  "perf_str_addr": "",
  "perf_city_name": "",
  "perf_st_code": "MD",
  "perf_st_name": "Maryland",
  "perf_zip_code": "207425141",
  "perf_ctry_code": "US",
  "perf_cong_dist": "04",
  "perf_st_cong_dist": "MD04",
  "perf_ctry_name": "United States",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "723600",
   "pgm_ele_name": "BioP-Biophotonics"
  }
 ],
 "pgm_ref": null,
 "app_fund": [
  {
   "app_code": "0116",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "040100",
   "fund_code": "01001617DB",
   "fund_name": "NSF RESEARCH & RELATED ACTIVIT",
   "fund_symb_id": "040100"
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2016,
   "fund_oblg_amt": 86868.0
  }
 ],
 "por": {
  "por_cntn": "<div class=\"porColContainerWBG\">\n<div class=\"porContentCol\"><p><strong>Background: </strong>Fluorescence molecular imaging technologies have the potential to improve the understanding of disease development, enable early diagnosis, and ultimately enhance treatment efficacy, leading to significant advances in public health. Over the past ten years there have been major increases in research and development efforts in academia and industry to develop drug-device combination products based on fluorescence imaging and molecular-specific contrast agents. Recently, submissions in this area have begun to arrive at FDA. While the development of fluorescence molecular imaging exhibits tremendous potential for clinical improvements, there remains a lack of standardized test methods for objective, quantitative characterization of device performance. The development of standardized tests for fluorescence molecular imaging devices can improve the speed and rigor of the regulatory process by facilitating preclinical characterization of device performance. <em>In vivo</em> molecular imaging measurements can provide insights into the strengths and limitations of phantom-based approaches; they can also shed light on considerations for design of preclinical and clinical studies for IDE, 510(k), and PMA submissions.</p>\n<p><strong>Results: </strong>In the present study, we have fabricated and validated two sets of 3D-printed (3DP) phantoms.&nbsp; The first set exhibits idealized geometries (e.g., spherical and cylindrical inclusions of varying sizes and depths). The second set is biomimetic phantoms for fluorescence molecular imaging. We evaluated the optical accuracy of phantom materials through spectrophotometry and spectrofluorometry, and morphology with micro-CT imaging. Stability was also evaluated by repeated measurement over a period of months. In addition, we performed <em>in vivo</em> rodent model study to assess the utility of 3DP phantom testing. The results of phantom-based measurements were compared with <em>in vivo</em> images of fluorescent-labeled tumors to evaluate the ability of these test methods to predict <em>in vivo</em> performance and to identify limitations. Measurements were performed with a scientific CCD camera as well as near-IR-enabled mobile phones. This project has published one journal paper and two conference proceedings in internationally reputed platform.</p>\n<p><strong>Intellectual Merits: </strong>This work elucidates optimal fabrication approaches and key factors that influence the effectiveness of 3D-printed phantoms. Thus, it provides a foundation for a novel area of regulatory science with extensive potential for enabling rigorous, quantitative, objective device evaluation on the benchtop. This project also provides extensive insights into quantitative inter-comparison of fluorescence molecular imaging systems&rsquo; performance for understanding device- and contrast-agent-dependent effects. This project is very useful to clinical as well as industrial researchers and it helps the industrial researchers to bridge the gap between lab to bed implementation.</p>\n<p><strong>Broader Impact:</strong> This project contributes to healthcare through the development of well-validated 3DP phantoms that can be used by academic and industrial researchers to facilitate technological advancement and translation from laboratory to clinical implementation. This work leveraged the complementary expertise of two research groups at UMD and FDA to generate regulatory-relevant findings with high relevance to the biomedical engineering community. This project trains undergraduate and graduate students to prepare them the needed skillsets for their future career in this field. The PI and his FDA collaborator are both members of AAPM&rsquo;s Fluorescence-Guided Intervention Workgroup, which is working to standardize this technology.</p><br>\n<p>\n\t\t\t\t      \tLast Modified: 05/02/2019<br>\n\t\t\t\t\tModified by: Yu&nbsp;Chen</p>\n</div>\n<div class=\"porSideCol\"></div>\n</div>",
  "por_txt_cntn": "\nBackground: Fluorescence molecular imaging technologies have the potential to improve the understanding of disease development, enable early diagnosis, and ultimately enhance treatment efficacy, leading to significant advances in public health. Over the past ten years there have been major increases in research and development efforts in academia and industry to develop drug-device combination products based on fluorescence imaging and molecular-specific contrast agents. Recently, submissions in this area have begun to arrive at FDA. While the development of fluorescence molecular imaging exhibits tremendous potential for clinical improvements, there remains a lack of standardized test methods for objective, quantitative characterization of device performance. The development of standardized tests for fluorescence molecular imaging devices can improve the speed and rigor of the regulatory process by facilitating preclinical characterization of device performance. In vivo molecular imaging measurements can provide insights into the strengths and limitations of phantom-based approaches; they can also shed light on considerations for design of preclinical and clinical studies for IDE, 510(k), and PMA submissions.\n\nResults: In the present study, we have fabricated and validated two sets of 3D-printed (3DP) phantoms.  The first set exhibits idealized geometries (e.g., spherical and cylindrical inclusions of varying sizes and depths). The second set is biomimetic phantoms for fluorescence molecular imaging. We evaluated the optical accuracy of phantom materials through spectrophotometry and spectrofluorometry, and morphology with micro-CT imaging. Stability was also evaluated by repeated measurement over a period of months. In addition, we performed in vivo rodent model study to assess the utility of 3DP phantom testing. The results of phantom-based measurements were compared with in vivo images of fluorescent-labeled tumors to evaluate the ability of these test methods to predict in vivo performance and to identify limitations. Measurements were performed with a scientific CCD camera as well as near-IR-enabled mobile phones. This project has published one journal paper and two conference proceedings in internationally reputed platform.\n\nIntellectual Merits: This work elucidates optimal fabrication approaches and key factors that influence the effectiveness of 3D-printed phantoms. Thus, it provides a foundation for a novel area of regulatory science with extensive potential for enabling rigorous, quantitative, objective device evaluation on the benchtop. This project also provides extensive insights into quantitative inter-comparison of fluorescence molecular imaging systems? performance for understanding device- and contrast-agent-dependent effects. This project is very useful to clinical as well as industrial researchers and it helps the industrial researchers to bridge the gap between lab to bed implementation.\n\nBroader Impact: This project contributes to healthcare through the development of well-validated 3DP phantoms that can be used by academic and industrial researchers to facilitate technological advancement and translation from laboratory to clinical implementation. This work leveraged the complementary expertise of two research groups at UMD and FDA to generate regulatory-relevant findings with high relevance to the biomedical engineering community. This project trains undergraduate and graduate students to prepare them the needed skillsets for their future career in this field. The PI and his FDA collaborator are both members of AAPM?s Fluorescence-Guided Intervention Workgroup, which is working to standardize this technology.\n\n\t\t\t\t\tLast Modified: 05/02/2019\n\n\t\t\t\t\tSubmitted by: Yu Chen"
 }
}